Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Lymphoid Malignancies: Novel Transplantations Are Improving Outcomes
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Elevated Risk for Cause-Specific Mortality in Waldenström Macroglobulinemia
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Rituximab Failure Predicts Poor Outcome in DLBCL-Resembling Post-Transplant Lymphoproliferative Disorder
Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.
Phase 1 Trial Outcomes With Urelumab in Relapsed or Refractory B-Cell Lymphoma
Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.
Clinical Response to Tisagenlecleucel Confers HRQoL Benefit in Lymphoma
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Pixantrone or Gemcitabine and Rituximab for Relapsed, Aggressive B-Cell Non-Hodgkin Lymphoma
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Younger Age, Consolidation Therapy With Autologous SCT Associated With Improved OS in Patients With Primary CNS Lymphoma
Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.
Deepened Responses in Waldenström Macroglobulinemia After Rituximab
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Bendamustine Improves Event-Free Survival in Elderly Patients With Indolent B-Cell Lymphomas
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Reduced‐Intensity Conditioning May Improve Survival in Relapsed/Refractory Anaplastic Large Cell Lymphoma
Overall survival at 5 years was 100% with the reduced-intensity conditioning regimen compared with 48.5% with the myeloablative conditioning regimen.
Older Patients With Follicular Lymphoma Benefit From Appropriate Therapy
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Health-Related Quality of Life Unchanged With Lenalidomide Maintenance for DLBCL
Progression-free survival was superior with lenalidomide compared with placebo, while health-related quality of life was similar and did not change during the study.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Concomitant Diseases May Significantly Affect Outcomes in Patients With Mantle Cell Lymphoma
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma
Researchers characterized outcomes for enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, and peripheral gamma delta T-cell lymphoma.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Polatuzumab Vedotin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Influence of Facility Patient Volume on Mortality in Classical Hodgkin Lymphoma
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
Trace Metal Concentrations in Specimens of Patients With Lymphoma
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Pretreatment Vitamin D Deficiency Associated With Outcomes in Hodgkin Lymphoma
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging Mass Cytometry Reveals Prognostic Immune Phenotypes in DLBCL
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
Durvalumab Adds No Benefit to Single-Agent Ibrutinib in FL, DLBCL
The combination warrants no further study in these patients.
FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Nurse Practitioner-Led Rapid Diagnosis Clinic May Reduce Time to Diagnosis in Lymphoma
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Autoimmune Conditions Associated With Primary Central Nervous System Lymphoma
Significant associations were found between primary central nervous system lymphoma and systemic lupus erythematosus, myasthenia gravis, and uveitis.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Inferior Response Following Early Relapse in Frontline Treatment for Aggressive B-Cell Lymphomas
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
BAFF-R-CAR-T to Overcome Resistance: Q&A With Dr Hong Qin
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Long-Term Health Following the Lymphome Malin de Burkitt Chemotherapy Regimen
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Survival Disparities in Pediatric Patients With Lymphoma Based on Ethnicity
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
A Salvage Therapy Option for Follicular Lymphoma Makes Headway
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Want to read more?
Please login or register first to view this content.
